Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Author Correction: SMARCA2-regulated host cell factors are required for MxA restriction of influenza A viruses.

Dornfeld D, Dudek AH, Vausselin T, Günther SC, Hultquist JF, Giese S, Khokhlova-Cubberley D, Chew YC, Pache L, Krogan NJ, Garcia-Sastre A, Schwemmle M, Shaw ML.

Sci Rep. 2018 May 14;8(1):7782. doi: 10.1038/s41598-018-25858-y.

2.

SMARCA2-regulated host cell factors are required for MxA restriction of influenza A viruses.

Dornfeld D, Dudek AH, Vausselin T, Günther SC, Hultquist JF, Giese S, Khokhlova-Cubberley D, Chew YC, Pache L, Krogan NJ, Garcia-Sastre A, Schwemmle M, Shaw ML.

Sci Rep. 2018 Feb 1;8(1):2092. doi: 10.1038/s41598-018-20458-2. Erratum in: Sci Rep. 2018 May 14;8(1):7782.

3.

Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.

Vausselin T, Séron K, Lavie M, Mesalam AA, Lemasson M, Belouzard S, Fénéant L, Danneels A, Rouillé Y, Cocquerel L, Foquet L, Rosenberg AR, Wychowski C, Meuleman P, Melnyk P, Dubuisson J.

J Virol. 2016 Sep 12;90(19):8422-34. doi: 10.1128/JVI.00404-16. Print 2016 Oct 1.

4.

Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro.

Fénéant L, Ghosn J, Fouquet B, Helle F, Belouzard S, Vausselin T, Séron K, Delfraissy JF, Dubuisson J, Misrahi M, Cocquerel L.

PLoS One. 2015 Nov 12;10(11):e0142539. doi: 10.1371/journal.pone.0142539. eCollection 2015.

5.

High-Throughput Minigenome System for Identifying Small-Molecule Inhibitors of Ebola Virus Replication.

Edwards MR, Pietzsch C, Vausselin T, Shaw ML, Bukreyev A, Basler CF.

ACS Infect Dis. 2015 Aug 14;1(8):380-7. doi: 10.1021/acsinfecdis.5b00053. Epub 2015 Jun 24.

6.

New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A.

Fénéant L, Potel J, François C, Sané F, Douam F, Belouzard S, Calland N, Vausselin T, Rouillé Y, Descamps V, Baumert TF, Duverlie G, Lavillette D, Hober D, Dubuisson J, Wychowski C, Cocquerel L.

J Virol. 2015 Aug;89(16):8346-64. doi: 10.1128/JVI.00192-15. Epub 2015 Jun 3.

7.

Boronic acid-modified lipid nanocapsules: a novel platform for the highly efficient inhibition of hepatitis C viral entry.

Khanal M, Barras A, Vausselin T, Fénéant L, Boukherroub R, Siriwardena A, Dubuisson J, Szunerits S.

Nanoscale. 2015 Jan 28;7(4):1392-402. doi: 10.1039/c4nr03875d.

PMID:
25502878
8.

Phenylboronic-acid-modified nanoparticles: potential antiviral therapeutics.

Khanal M, Vausselin T, Barras A, Bande O, Turcheniuk K, Benazza M, Zaitsev V, Teodorescu CM, Boukherroub R, Siriwardena A, Dubuisson J, Szunerits S.

ACS Appl Mater Interfaces. 2013 Dec 11;5(23):12488-98. doi: 10.1021/am403770q. Epub 2013 Nov 19.

PMID:
24180242
9.

The antimalarial ferroquine is an inhibitor of hepatitis C virus.

Vausselin T, Calland N, Belouzard S, Descamps V, Douam F, Helle F, François C, Lavillette D, Duverlie G, Wahid A, Fénéant L, Cocquerel L, Guérardel Y, Wychowski C, Biot C, Dubuisson J.

Hepatology. 2013 Jul;58(1):86-97. doi: 10.1002/hep.26273. Epub 2013 May 14.

PMID:
23348596
10.

Regulatory T cells in HBV and HCV liver diseases: implication of regulatory T lymphocytes in the control of immune response.

Miroux C, Vausselin T, Delhem N.

Expert Opin Biol Ther. 2010 Nov;10(11):1563-72. doi: 10.1517/14712598.2010.529125. Epub 2010 Oct 11. Review.

PMID:
20932226

Supplemental Content

Loading ...
Support Center